{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T23:37:41Z","timestamp":1768520261005,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,1,13]],"date-time":"2010-01-13T00:00:00Z","timestamp":1263340800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1007\/s10067-009-1345-2","type":"journal-article","created":{"date-parts":[[2010,1,12]],"date-time":"2010-01-12T18:05:29Z","timestamp":1263319529000},"page":"487-493","source":"Crossref","is-referenced-by-count":12,"title":["Antibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis"],"prefix":"10.1007","volume":"29","author":[{"given":"Andrea","family":"Tesija-Kuna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simeon","family":"Grazio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marijana","family":"Miler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ines","family":"Vukasovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Porin","family":"Peric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nada","family":"Vrkic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,1,13]]},"reference":[{"issue":"Suppl","key":"1345_CR1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/ard.2004.032482","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P, Clegg DO, Nash P (2005) Psoriatic arthritis and psoriasis: classification, clinical features, pathophysiology, immunology, genetics. Ann Rheum Dis 64(Suppl):14\u201317","journal-title":"Ann Rheum Dis"},{"key":"1345_CR2","first-page":"127","volume":"62","author":"DD Gladman","year":"1987","unstructured":"Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK (1987) Psoriatic arthritis\u2014an analysis of 220 patients. Q J Med 62:127\u2013141","journal-title":"Q J Med"},{"key":"1345_CR3","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/rheumatology\/30.4.245","volume":"30","author":"JC Torre-Alonso","year":"1991","unstructured":"Torre-Alonso JC, Rodrigues-Perez A, Arribas-Castrillom JM, Ballina Garcia J, Riestra Noriega JL, Lopez Larrea C (1991) Psoriatic arthritis (PA): a clinical immunologic and radiological study. Brit J Rheumatol 30:245\u2013250","journal-title":"Brit J Rheumatol"},{"key":"1345_CR4","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/rheumatology\/keg217","volume":"42","author":"NJ McHugh","year":"2003","unstructured":"McHugh NJ, Balachrishnan C, Jones SM (2003) Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology Oxford 42:778\u2013783","journal-title":"Rheumatology Oxford"},{"issue":"Suppl. 39","key":"1345_CR5","first-page":"S69","volume":"23","author":"JP Riedmann","year":"2005","unstructured":"Riedmann JP, Munoz S, Kavanaugh A (2005) The use of second generation anti-CCP antibody (anti-CCP2) testing in rheumatoid arthritis\u2014a systematic review. Clin Exp Rheumatol 23(Suppl. 39):S69\u2013S76","journal-title":"Clin Exp Rheumatol"},{"key":"1345_CR6","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1136\/ard.2004.033571","volume":"64","author":"J R\u00f6nnelid","year":"2005","unstructured":"R\u00f6nnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, van Vollenhoven RF (2005) Longitudinal analysis of citrullinated protein\/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 64:1744\u20131749","journal-title":"Ann Rheum Dis"},{"key":"1345_CR7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/art.20044","volume":"50","author":"FA Gaalen Van","year":"2004","unstructured":"Van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BAW, Breedveld FC, Verweij CL et al (2004) Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis. Arthritis Rheum 50:709\u2013715","journal-title":"Arthritis Rheum"},{"key":"1345_CR8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cccn.2004.07.016","volume":"350","author":"S Nijenhuis","year":"2004","unstructured":"Nijenhuis S, Zendman AJ, Vossenaar ER, Pruijn GJ, van Venrooij WJ (2004) Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. Clin Chim Acta 350:17\u201334","journal-title":"Clin Chim Acta"},{"issue":"6","key":"1345_CR9","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.4049\/jimmunol.166.6.4177","volume":"166","author":"C Masson-Bessiere","year":"2001","unstructured":"Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T, Serre G (2001) The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 166(6):4177\u20134184","journal-title":"J Immunol"},{"issue":"11","key":"1345_CR10","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/rheumatology\/kei023","volume":"44","author":"X Chang","year":"2005","unstructured":"Chang X, Yamada R, Suzuki A, Kochi Y, Sawada T, Yamamoto K (2005) Citrullination of fibronectin in rheumatoid arthritis synovial tissue. Rheumatology 44(11):1374\u20131382","journal-title":"Rheumatology"},{"key":"1345_CR11","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bbrc.2005.05.137","volume":"333","author":"A Suzuki","year":"2005","unstructured":"Suzuki A, Yamad R, Ohtake-Yamanaka M, Okazaki Y, Sawada T, Yamamoto K (2005) Anti-citrullinated collagen type I antibody is a target of autoimmunity in rheumatoid arthritis. Biochem Biophys res Commun 333:418\u2013426","journal-title":"Biochem Biophys res Commun"},{"key":"1345_CR12","doi-asserted-by":"crossref","first-page":"R1421","DOI":"10.1186\/ar1845","volume":"7","author":"A Kinloch","year":"2005","unstructured":"Kinloch A, Tatzer V, Wait R, Peston D, Lundberg K, Donatien P et al (2005) Identification of citrullinated \u03b1-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 7:R1421\u2013R1429","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"1345_CR13","doi-asserted-by":"crossref","first-page":"R142","DOI":"10.1186\/ar1149","volume":"6","author":"ER Vossenaar","year":"2004","unstructured":"Vossenaar ER, Despres N, Lapointe E, van der Heijden A, Lora M, Senshu T et al (2004) Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 6(2):R142\u2013R150","journal-title":"Arthritis Res Ther"},{"key":"1345_CR14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/bies.10246","volume":"25","author":"SV Strelkov","year":"2003","unstructured":"Strelkov SV, Herrmann H, Aebi U (2003) Molecular architecture of intermediate filaments. Bioassays 25:243\u2013251","journal-title":"Bioassays"},{"issue":"8","key":"1345_CR15","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1002\/art.22817","volume":"56","author":"H Bang","year":"2007","unstructured":"Bang H, Egerer K, Gauliard A, L\u03cbthke K, Rudolph PE, Fredenhagen G et al (2007) Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 56(8):2503\u20132511","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1345_CR16","doi-asserted-by":"crossref","first-page":"R119","DOI":"10.1186\/ar2008","volume":"8","author":"C Dejaco","year":"2006","unstructured":"Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M (2006) Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 8(4):R119","journal-title":"Arthritis Res Ther"},{"key":"1345_CR17","first-page":"1658","volume":"34","author":"L Soos","year":"2007","unstructured":"Soos L, Szekanecz Z, Szabo Z, Fekete A, Zeher M, Horvath IF et al (2007) Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. J Rheumatol 34:1658\u20131663","journal-title":"J Rheumatol"},{"key":"1345_CR18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/art.23188","volume":"58","author":"L Mathsson","year":"2008","unstructured":"Mathsson L, Mullazehi M, Wick MC, Sj\u00f6berg O, van Vollenhoven R, Klareskog L, R\u00f6nnelid J (2008) Antibodies against citrullinated vimentin in rheumatoid arthritis. Higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 58:36\u201345","journal-title":"Arthritis Rheum"},{"key":"1345_CR19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s12016-007-8016-3","volume":"34","author":"H Poulsom","year":"2008","unstructured":"Poulsom H, Charles PJ (2008) Antibodies to citrullinated vimentin are a specific and sensitive marker for the diagnosis of rheumatoid arthritis. Clinic Rev Allerg Immunol 34:4\u201310","journal-title":"Clinic Rev Allerg Immunol"},{"key":"1345_CR20","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C et al (1995) American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727\u2013735","journal-title":"Arthritis Rheum"},{"key":"1345_CR21","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/ard.62.2.127","volume":"62","author":"L Heuft-Dorenbosch","year":"2003","unstructured":"Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landew\u00e9 R, van der Tempel H, Mielantset H et al (2003) Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 62:127\u2013132","journal-title":"Ann Rheum Dis"},{"key":"1345_CR22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van\u2019t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44\u201348","journal-title":"Arthritis Rheum"},{"key":"1345_CR23","first-page":"886","volume":"22","author":"M Blackmore","year":"1995","unstructured":"Blackmore M, Gladman DD, Husted J, Long J, Farewell VT (1995) Measuring health status in psoriatic arthritis: the health assessment questionnaire and its modification. J Rheumatol 22:886\u2013893","journal-title":"J Rheumatol"},{"key":"1345_CR24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/archderm.1989.01670140087017","volume":"125","author":"R Marks","year":"1989","unstructured":"Marks R, Barton SP, Shuttleworth D, Finlay AY (1989) Assessment of disease progress in psoriasis. Arch Dermatol 125:235\u2013240","journal-title":"Arch Dermatol"},{"key":"1345_CR25","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","volume":"157","author":"T Fredriksson","year":"1978","unstructured":"Fredriksson T, Pettersson U (1978) Severe psoriasis: oral therapy with a new retinoid. Dermatologica 157:238\u2013244","journal-title":"Dermatologica"},{"key":"1345_CR26","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-1-79","volume":"16","author":"K Webster","year":"2003","unstructured":"Webster K, Cella D, Yost K (2003) The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 16:79","journal-title":"Health Qual Life Outcomes"},{"key":"1345_CR27","first-page":"811","volume":"32","author":"D Cella","year":"2005","unstructured":"Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J (2005) Validation of the functional assessment of chronic illness therapy fatigue scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 32:811\u2013819","journal-title":"J Rheumatol"},{"key":"1345_CR28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"ME Weinblatt","year":"2003","unstructured":"Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA et al (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48:35\u201345","journal-title":"Arthritis Rheum"},{"key":"1345_CR29","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1136\/ard.2003.012211","volume":"63","author":"ER Vossenar","year":"2004","unstructured":"Vossenar ER, Radstake TR, van der Heijden A, van Mansum MA, Dieteren C, de Rooij DJ et al (2004) Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis 63:373\u2013381","journal-title":"Ann Rheum Dis"},{"issue":"Suppl II","key":"1345_CR30","first-page":"648","volume":"65","author":"K Brickmann","year":"2006","unstructured":"Brickmann K, Yazdani-Biuki BJ, M\u03cbller T, Graninger WB, Brezinschek HP (2006) Anti-mutated-citrullinated-vimentin antibodies (MCV) in psoriatic arthritis. (Abstract) Ann Rheum Dis 65(Suppl II):648","journal-title":"(Abstract) Ann Rheum Dis"},{"key":"1345_CR31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12016-008-8073-2","volume":"34","author":"N Fabien","year":"2008","unstructured":"Fabien N, Olson NO, Goetz J, Johanet C, Escande A, Bardin N et al (2008) Prevalence of autoantibodies to cyclic citrullinated peptide in patients with rheumatic diseases other than rheumatoid arthritis: a French multicenter study. Clinic Rev Allerg Immunol 34:40\u201344","journal-title":"Clinic Rev Allerg Immunol"},{"key":"1345_CR32","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1136\/ard.2005.040998","volume":"65","author":"GM Alenius","year":"2006","unstructured":"Alenius GM, Berglin E, Rantap\u00e4\u00e4-Dahlqvist S (2006) Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation. Ann Rheum Dis 65:398\u2013400","journal-title":"Ann Rheum Dis"},{"key":"1345_CR33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10067-006-0214-5","volume":"26","author":"N Inanc","year":"2007","unstructured":"Inanc N, Dalkilic E, Kamali S, Kasapoglu-G\u00fcnal E, Elbir Y, Direskeneli H, Inanc M (2007) Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol 26:17\u201323","journal-title":"Clin Rheumatol"},{"key":"1345_CR34","first-page":"511","volume":"32","author":"L Bogliolo","year":"2005","unstructured":"Bogliolo L, Alpini C, Caporali R, Scir\u00e8 CA, Moratti R, Montecucco C (2005) Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J Rheumatol 32:511\u2013515","journal-title":"J Rheumatol"},{"key":"1345_CR35","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/ard.2004.032177","volume":"64","author":"BV Cruyssen","year":"2005","unstructured":"Cruyssen BV, Hoffman IEA, Zmierczak H, Van den Berghe M, Kruithof E, De Rycke L et al (2005) Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 64:1145\u20131149","journal-title":"Ann Rheum Dis"},{"key":"1345_CR36","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/rheumatology\/keg217","volume":"42","author":"NJ McHugh","year":"2003","unstructured":"McHugh NJ, Balachrishnan C, Jones SM (2003) Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology 42:778\u2013783","journal-title":"Rheumatology"},{"key":"1345_CR37","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1002\/art.11223","volume":"48","author":"S Rantapaa-Dahlqvist","year":"2003","unstructured":"Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H et al (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741\u20132749","journal-title":"Arthritis Rheum"},{"key":"1345_CR38","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/art.20018","volume":"50","author":"MM Nielen","year":"2004","unstructured":"Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH et al (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50:380\u2013386","journal-title":"Arthritis Rheum"},{"key":"1345_CR39","first-page":"1","volume":"35","author":"L Innala","year":"2008","unstructured":"Innala L, Kokkonen H, Eriksson C, Jiddell E, Berglin E, Rantapaa-Dahlqvist S (2008) Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24\u00a0months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 35:1\u20137","journal-title":"J Rheumatol"},{"key":"1345_CR40","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1136\/ard.2003.016808","volume":"63","author":"A Kastbom","year":"2004","unstructured":"Kastbom A, Strandberg G, Lindroos A, Skogh T (2004) Anti-CCP antibody test predicts the disease course during 3\u00a0years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 63:1085\u20131089","journal-title":"Ann Rheum Dis"},{"key":"1345_CR41","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1002\/art.20659","volume":"50","author":"TR Mikuls","year":"2004","unstructured":"Mikuls TR, O\u2019Dell JR, Stoner JA, Parrish LA, Arend WP, Norris JM, Holers VM (2004) Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum 50:3776\u20133782","journal-title":"Arthritis Rheum"},{"key":"1345_CR42","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00296-004-0571-9","volume":"26","author":"P Caramaschi","year":"2005","unstructured":"Caramaschi P, Biasi D, Tonolli E, Pieropan S, Martinelli N, Carletto A et al (2005) Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. Rheumatol Int 26:58\u201362","journal-title":"Rheumatol Int"},{"key":"1345_CR43","first-page":"497","volume":"33","author":"Y Braun-Moscovici","year":"2006","unstructured":"Braun-Moscovici Y, Markovits D, Zinder O, Schapira D, Rozin A, Ehrenburg M et al (2006) Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-\u03b1 therapy in patients with rheumatoid arthritis. J Rheumatol 33:497\u2013500","journal-title":"J Rheumatol"},{"key":"1345_CR44","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/ard.2005.038851","volume":"65","author":"HA Chen","year":"2006","unstructured":"Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, Chang HN et al (2006) The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 65:35\u201339","journal-title":"Ann Rheum Dis"},{"key":"1345_CR45","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1136\/ard.2003.014647","volume":"63","author":"C Alessandri","year":"2004","unstructured":"Alessandri C, Bombardieri M, Pap N, Cinquini M, Magrini L, Tincani A, Valesini G (2004) Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF alpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 63:1218\u20131221","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-009-1345-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-009-1345-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-009-1345-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T17:43:26Z","timestamp":1739727806000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-009-1345-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,13]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["1345"],"URL":"https:\/\/doi.org\/10.1007\/s10067-009-1345-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,13]]}}}